Linical Co., Ltd. (TYO:2183)

Market Cap	4.65B -39.8%
Revenue (ttm)	7.95B -21.6%
Net Income	-3.79B
EPS	-167.72
Shares Out	22.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	8.00 (3.90%)
Ex-Dividend Date	Mar 30, 2026

Volume	13,900
Open	206.00
Previous Close	206.00
Day's Range	206.00 - 207.00
52-Week Range	198.00 - 355.00
Beta	0.39
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Linical

Linical Co., Ltd., a global contract research organization, provides full spectrum of drug development services to pharmaceutical companies worldwide. The company offers drug discovery consulting services, such as market analysis and research of products in development, regulatory affairs, and licensing support. It also provides clinical trial evaluation, statistical analysis, medical writing, pharmacovigilance, clinical monitoring, and contract medical affairs services. The company was incorporated in 2005 and is headquartered in Osaka, Japan.

• Industry: Specialty Business Services
• Sector: Industrials
• Founded: 2005
• Employees: 577
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 2183

Financial Performance

In fiscal year 2026, Linical's revenue was 8.67 billion, a decrease of -16.98% compared to the previous year's 10.44 billion. Losses were -3.33 billion, 517.6% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 26, 2026

Data Sources Report a data error